These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 8593019)
21. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Gao Q; Gu Z; Hiscott J; Dionne G; Wainberg MA Antimicrob Agents Chemother; 1993 Jan; 37(1):130-3. PubMed ID: 8381634 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus. Frick LW; Lambe CU; St John L; Taylor LC; Nelson DJ Antimicrob Agents Chemother; 1994 Dec; 38(12):2722-9. PubMed ID: 7695253 [TBL] [Abstract][Full Text] [Related]
23. Comparative pharmacokinetics of Racivir, (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Hurwitz SJ; Otto MJ; Schinazi RF Antivir Chem Chemother; 2005; 16(2):117-27. PubMed ID: 15889534 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Riva L; Blaney SM; Dauser R; Nuchtern JG; Durfee J; McGuffey L; Berg SL Clin Cancer Res; 2000 Mar; 6(3):994-7. PubMed ID: 10741726 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats. Abobo CV; Ni L; Schinazi RF; Liotta DC; Boudinot FD J Pharm Sci; 1994 Jan; 83(1):96-9. PubMed ID: 8138919 [TBL] [Abstract][Full Text] [Related]
26. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group. Lewis LL; Venzon D; Church J; Farley M; Wheeler S; Keller A; Rubin M; Yuen G; Mueller B; Sloas M; Wood L; Balis F; Shearer GM; Brouwers P; Goldsmith J; Pizzo PA J Infect Dis; 1996 Jul; 174(1):16-25. PubMed ID: 8655986 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of dideoxypurine nucleoside analogs in plasma and cerebrospinal fluid of rhesus monkeys. Hawkins ME; Mitsuya H; McCully CM; Godwin KS; Murakami K; Poplack DG; Balis FM Antimicrob Agents Chemother; 1995 Jun; 39(6):1259-64. PubMed ID: 7574512 [TBL] [Abstract][Full Text] [Related]
34. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735 [TBL] [Abstract][Full Text] [Related]
35. Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina. Tuntland T; Nosbisch C; Baughman WL; Massarella J; Unadkat JD Am J Obstet Gynecol; 1996 Mar; 174(3):856-63. PubMed ID: 8633656 [TBL] [Abstract][Full Text] [Related]
36. Enzymatic production of optically pure (2'R-cis)-2'-deoxy-3'-thiacytidine (3TC, lamivudine): a potent anti-HIV agent. Mahmoudian M; Baines BS; Drake CS; Hale RS; Jones P; Piercey JE; Montgomery DS; Purvis IJ; Storer R; Dawson MJ Enzyme Microb Technol; 1993 Sep; 15(9):749-55. PubMed ID: 7764073 [TBL] [Abstract][Full Text] [Related]
37. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Meany HJ; Fox E; McCully C; Tucker C; Balis FM Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus. Williams PE; Muirhead GJ; Sereni D; Rousseau FS; Edelman K; Hooker M Br J Clin Pharmacol; 1993 Mar; 35(3):255-60. PubMed ID: 8385974 [TBL] [Abstract][Full Text] [Related]
39. Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina). Tuntland T; Nosbisch C; Unadkat JD J Antimicrob Chemother; 1997 Nov; 40(5):687-93. PubMed ID: 9421317 [TBL] [Abstract][Full Text] [Related]
40. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]